Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow

David P. Steensma, Ruben A. Mesa, Terra L. Reeder, Ayalew Tefferi, Scott H. Kaufmann

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Previous studies demonstrated that ∼50% of acute myelogenous leukemia samples exhibit activation of the mitogen-activated protein kinase (MAPK) pathway and growth inhibition by MEK inhibitors. To extend these observations, we assessed MAPK pathway activation and effects of CI-1040 in normal and myelodysplastic (MDS) marrow.

Original languageEnglish (US)
Pages (from-to)1072-1074
Number of pages3
JournalHaematologica
Volume88
Issue number9
StatePublished - Sep 1 2003
Externally publishedYes

Keywords

  • MAPK
  • MEK inhibitors

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow'. Together they form a unique fingerprint.

  • Cite this

    Steensma, D. P., Mesa, R. A., Reeder, T. L., Tefferi, A., & Kaufmann, S. H. (2003). Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow. Haematologica, 88(9), 1072-1074.